Literature DB >> 8087448

Percutaneous insertion of Hickman catheters while the patient is in bed: a simplification of the technique.

M Morales1, J Dorta.   

Abstract

Central-venous long-term catheters are an important tool for patients undergoing anticancer chemotherapy. To circumvent dependence on the surgical department and their waiting lists, catheters were placed while the patient was in bed in the ward of a general oncology unit. A total of 84 single-lumen Hickman catheters were inserted with aseptic technique, percutaneously in this setting. The complication rate after the insertion was low, with only 1 case of pneumothorax (1.2%) and 7.1% of patients suffering arterial puncture. The placement of Hickman catheters while the patient is in bed is a safe procedure that can save hospitalization costs and permits the insertion at the optimum time in the care of the patient.

Entities:  

Mesh:

Year:  1994        PMID: 8087448     DOI: 10.1007/bf00365735

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  2 in total

1.  Fifty-five patient years' experience with a totally implanted system for intravenous chemotherapy.

Authors:  H Brincker; G Saeter
Journal:  Cancer       Date:  1986-03-15       Impact factor: 6.860

2.  Experience with subcutaneous infusion ports in three hundred patients.

Authors:  T E Brothers; L K Von Moll; J E Niederhuber; J A Roberts; S Walker-Andrews; W D Ensminger
Journal:  Surg Gynecol Obstet       Date:  1988-04
  2 in total
  2 in total

1.  Patterns of use of vascular access devices in patients undergoing hematopoietic stem cell transplantation: results of an international survey.

Authors:  Juan J Toro; Manuel Morales; Fausto Loberiza; Jose L Ochoa-Bayona; Cesar O Freytes
Journal:  Support Care Cancer       Date:  2007-05-08       Impact factor: 3.603

Review 2.  Superior vena cava thrombosis secondary to hickman catheter and complete resolution after fibrinolytic therapy.

Authors:  M Morales; M Llanos; J Dorta
Journal:  Support Care Cancer       Date:  1997-01       Impact factor: 3.603

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.